The dried blood spot collection cards market size is estimated to be USD 379.5 million in 2022 and is expected to witness a CAGR of 5.12% during the forecast period 2023-2033. Increasing basic use in newborn screening, rising adoption in forensic toxicology applications, rise in the use of dried blood spot collection cards for therapeutic medication monitoring and expanding affiliations between private and public organisations to develop diagnostic product are projected to drive the market growth in near future. Additionally, escalating government efforts, public-private partnerships, and collaborations that aim to boost usage and increasing awareness of diagnostic products are contributing the market growth. However, technological challenges when using dried blood spot collection cards to obtain blood samples from the aging population are predicted to limit market growth are expected to restrain the market growth.

Escalating government efforts, public-private partnerships, or collaborations that aim to boost usage and increasing awareness of diagnostic products are projected to increase demand in the market in the years to come. For instance, the Indian government proposed building critical care hospital blocks in 12 central institutions and 602 districts, combined public health laboratories in the majority of the districts, 3,382 public block units in 11 states, and merged public health laboratories in the majority of the districts. Additionally, 17,000 or more rural and 11,000 or more urban health and wellness institutions will receive funding.

Rise in the use of dried blood spot collection cards for therapeutic medication monitoring is anticipated to spur market expansion. For instance, a study to evaluate the viability of at-home dried blood spot collection combined with PCR as a method for malaria research was carried out by researchers from the University of Washington and Med Biotech Laboratories in July 2022.

Segmentation

By Card Type

The market is categorized into FTA, whatman 903, ahlstrom 226, and others. In 2022, the whatman 903 segment accounted for the highest revenue share due to its effectiveness and safety in sample identification, collecting, and transport. Whatman paper is a particular kind of filter paper that is frequently used in qualitative research. The filter paper is made from premium cotton linters and has cellulose fibres in it. Another important aspect that is estimated to have a considerable impact on market expansion in the near future is the growing use of the Whatman card type in various research investigations. For instance, a study to evaluate the Whatman FTA cards use in molecular diagnosis for detecting Yellow fever virus was undertaken in June 2022 by a team of researchers from the Division of Vector-Borne Diseases, Fort Collins (YFV). According to the study, the card can be inexpensive and simple to use in the molecular diagnosis of yellow fever.

By Application

On the basis of application, the market is categorized into infectious disease testing, new born screenings, forensics, CRO/research, therapeutic drug monitoring, and others. In the global market, the new born screenings segment accounted for the largest revenue share in 2022 owing to growing newborn screening. For instance, the National Organization for Rare Disorders forecasts that in the United States in 2021, approximately 4 million infants were screened through the collection of blood samples from the newborn’s heel before being released from a hospital or birthing facility due to the high prevalence of certain metabolic errors, endocrinopathies, and hearing loss, all of which can significantly increase morbidity. According to this, NHS England amended its recommendations for the U.K.’s newborn blood spot (NBS) screening programme for cystic fibrosis (CF) in May 2022. The guidelines are regarded as a reference manual for labs. An initial dried blood sample is used for IRT analysis as part of the standard process.

Regional Markets

In 2022, North America region accounted for the highest revenue in the dried blood spot collection cards market and is expected to maintain its dominance during the forecast period. This is attributed to increase of government programmes for newborn screening testing and the expansion of research into using DBS collecting cards for other purposes. Every newborn in the United States needs to undergo screening as part of routine medical care, however each state has a distinct financial allocation, the price of newborn screening tests differs from state to state. Health insurance or other programmes cover the cost of the screening. Babies will therefore undergo the screening regardless of their health insurance status. The Asia Pacific market is predicted to see the fastest CAGR, owing to existence of a sizable target population in nations like India, China, Japan, and South Korea. One of the main reasons propelling the regional market is the expanding use of cutting-edge laboratory techniques and procedures, such as dried blood spot collection cards for quicker investigation and diagnosis of infectious and chronic disorders.

Competitor Insights

Some of the key players operating in the dried blood spot collection cards market are Perkinelmer, Pall Corporation, Roche, QIAGEN, Eastern Business Forms, Inc., Ahlstrom-Munksjö, Archimed Life Science Gmbh, Shimadzu Corporation, and Centogene N.V.

• To increase their market share, major players use a variety of growth strategies, including the launch of new products, the differentiation of their existing products, and the extension of their geographic reach. For instance, PerkinElmer introduced a dried blood spot collection cards-based COVID-19 serology test in July 2020 using the GSP/DELFIA Platform, which allows for the processing of 5,000 samples.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including card type and application from 2022 to 2033.

Report Scope:

Segmentation: Dried Blood Spot Collection Cards Market Report 2022 – 2033

Card Type (Revenue, USD Million), 2022 – 2033

• FTA
• Whatman 903
• Ahlstrom 226
• Others

Application (Revenue, USD Million), 2022 – 2033

• Infectious Disease Testing
• New Born Screenings
• Forensics
• CRO/Research
• Therapeutic Drug Monitoring
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA